Abstract
To unravel the source of SARS-CoV-2 introduction and the pattern of its spreading and evolution in the United Arab Emirates, we conducted meta-transcriptome sequencing of 1,067 nasopharyngeal swab samples collected between May 9th and Jun 29th, 2020 during the first peak of the local COVID-19 epidemic. We identified global clade distribution and eleven novel genetic variants that were almost absent in the rest of the world defined five subclades specific to the UAE viral population. Cross-settlement human-to-human transmission was related to the local business activity. Perhaps surprisingly, at least 5% of the population were co-infected by SARS-CoV-2 of multiple clades within the same host. We also discovered an enrichment of cytosine-to-uracil mutation among the viral population collected from the nasopharynx, that is different from the adenosine-to-inosine change previously reported in the bronchoalveolar lavage fluid samples and a previously unidentified upregulation of APOBEC4 expression in nasopharynx among infected patients, indicating the innate immune host response mediated by ADAR and APOBEC gene families could be tissue-specific. The genomic epidemiological and molecular biological knowledge reported here provides new insights for the SARS-CoV-2 evolution and transmission and points out future direction on host-pathogen interaction investigation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Department of Health of Abu Dhabi, UAE and National Natural Science Foundation of China.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The overall research plan was reviewed and approved by the EthicsCommittees of BGI-Shenzhen (No. BGI-IRB 20143) and Department of Health of United Arab Emirates(DOH/CVDC/2020/1945) on the collect of SARS-CoV-2 virus.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
manuscript update; Figure 1 & 4 revised; author affiliations updated; Supplemental files updated;
Data Availability
A total of 896 high quality consensus assemblies (with less than 2% gaps) were submitted to GISAID (EPI_ISL_698105-698169, EPI_ISL_698172-699161, EPI_ISL_708827-708838) and raw sequencing data aligned to the SARS-CoV-2 reference genome were uploaded to NCBI (PRJNA687136) . We combined our genomes with other publicly available sequences for a final dataset of 973 SARS-CoV-2 genomes(ncov_global.json, Supplementary file). The dataset can be visualized on the community Nextstrain page.
